Genzyme-backed 4s3 Secures Venture Capital Funding

Privately-held 4s3 Bioscience, Inc. has received $20 million in funding for plans to focus its research on neuromuscular diseases, including ALS. The funds will support development of its drug delivery platform technology to enable targeted delivery of macromolecules specifically to skeletal muscles.

Click here to read more.

Share this: